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ABSTRACT
Introduction: Chronic kidney disease (CKD) is characterized by slow, progressive, 
and irreversible loss of kidney function. CKD has become a serious public health issue 
because of its increasing morbidity and mortality rates. The present study aimed to 
investigate factors associated with hematomas caused by arteriovenous fistula (AVF) at 
a Renal Replacement Therapy Unit in the state of Rio Grande do Sul, southern Brazil.
Methods: In this cross-sectional study, 72 patients with CKD aged 18 years or over, 
presenting with AVF, and undergoing three hemodialysis sessions per week were 
evaluated from June 2014 to March 2015. Prevalence ratios (PRs) with 95% confidence 
intervals (95% CIs) were estimated for identification of risk factors associated with 
AVF. P-values < 0.05 were considered significant.
Results: Sex, age, self-reported skin color, educational level, hypertension, 
diabetes, nephrotic syndrome, congestive heart failure, and hepatitis C were not 
associated with hematoma formation (i.e., all estimated PRs had p-values > 0.05). 
The single factor associated with hematomas was AVF time shorter than 60 days 
(PR = 2.04; 95% CI: 1.28-3.27; p < 0.01).
Conclusion: AVF maturation time was associated with higher prevalence of hematomas 
at the cannulation site. Therefore, AVF time should be given special attention in patients 
undergoing renal therapy at dialysis centers.
Keywords: Arteriovenous fistula; hematoma; chronic renal failure
Chronic kidney disease (CKD) is characterized by slow, progressive, 
and irreversible loss of kidney function with biochemical and physiological 
deterioration of the renal system, leading to accumulation of toxins in the body 
and hydroelectrolytic and hormonal unbalance1-2. CKD diagnosis is defined as 
glomerular filtration rate (GFR) < 60 mL/min/1.73 m or GFR ≥ 60 mL/min/1.73 m in 
patients with a marker of renal parenchymal damage (e.g., albuminuria) for 
more than 3 months2-4. CKD has become a public health issue because of its 
increasing morbidity and mortality rates as well as high maintenance costs 
of renal replacement therapies, such as hemodialysis, peritoneal dialysis, 
and kidney transplantation1.
According to global health estimates, CKD accounted for 864,226 deaths 
(i.e., 1.5% of all deaths worldwide) in 2012, being the 14th leading cause 
of deaths that year5. In Brazil, current data show that mortality due to CKD 
is approximately 15% in renal replacement therapy services6. The major 
contributing cause of mortality in this group of patients is cardiovascular 
disease, regardless of other classic risk factors such as age, ethnicity, sex, 
and underlying comorbidities (e.g., diabetes)6.
http://seer.ufrgs.br/hcpaClin Biomed Res 2018;38(3)254
Medeiros et al.
In patients with CKD, conventional hemodialysis 
can be performed through different types of vascular 
access, including central venous catheter and 
arteriovenous fistula (AVF)7. An AVF consists of a 
subcutaneous anastomosis between an artery and 
an adjacent vein, with dilation of superficial veins, 
allowing constant circulation and repeated needle 
insertion8,9.
A major complication in AVF management is 
post-cannulation hematoma. Hematomas may 
present with several forms according to a patient’s 
hemostatic state as well as blood volume and time of 
blood confinement at the cannulation site7,8. Period of 
cannulation, use of anticoagulation, and dose and 
type of anticoagulant are factors which contribute 
to hematoma formation8,9. Thus, an adequate 
cannulation technique is essential for preventing AVF 
hematomas. Hematomas are a major complication 
because they impair the process of cannulation 
and, therefore, dialysis, affecting directly the quality 
of life of a patient with kidney disease. In addition, 
hematomas contribute to complications such as AVF 
thrombosis and stenosis8,9.
The present study aimed to investigate factors 
associated with AVF hematomas at a teaching 
hospital’s Renal Replacement Therapy Unit (RRTU) 
in the state of Rio Grande do Sul, southern Brazil, 
in the period of 2014-2015.
METHODS
Design and Location
This retrospective, cross-sectional study was 
conducted at a teaching hospital’s RRTU in a 
municipality located in the state of Rio Grande do 
Sul. The hospital is a referral center for 49 nearby 
municipalities. Users are covered by the Brazilian 
Unified Health System (Sistema Único de Saúde, 
SUS).
Inclusion Criteria and Data Collection
The following inclusion criteria were used: patients 
with CKD, aged 18 years or over, presenting with 
AVF, and undergoing three hemodialysis sessions 
per week, from June 2014 to March 2015. Data were 
collected from a RRTU spreadsheet containing 
indicators measuring the monthly risk of hematoma 
formation due to AVF. This instrument included the 
following variables: sex, age, self-reported skin 
color, educational level, occupation, AVF time, 
professional in charge of AVF cannulation, and 
length of experience of this professional. In addition, 
it informed whether a patient had the following 
comorbidities: hypertension, diabetes, nephrotic 
syndrome, congestive heart failure, and hepatitis C.
AVF Creation and Anticoagulation During 
Dialysis
In all patients, AVF was created using Nipro 
Medical Corporation 17G needles. Anticoagulation 
was performed at the beginning of dialysis using a 
bolus of heparin according to each patient’s body 
weight and coagulation state, with doses ranging 
from 2000 to 5000 UI/mL. The process of dialysis 
lasted for approximately 4 hours.
Sample Size Calculation
Epi InfoTM software was used for estimating the 
size of the study sample, considering an expected 
outcome prevalence of 40%10, a maximum error 
of ± 4%, and a confidence level of 95%. Thus, the 
initial sample size was calculated at 65 patients. 
To compensate for losses, the sample was increased 
by 10%, resulting in a total of 72 patients.
Ethical Considerations
This study was conducted in accordance with 
regulatory standards and guidelines of research 
involving humans, as defined by resolution no. 466/2012 
of the Brazilian National Health Council (protocol 
no. 37/2014).
Statistical Analysis
Data were analyzed using IBM SPSS software, 
version 23.0. For continuous data, normality was 
assessed using Kolmogorov-Smirnov test, with 
Lilliefors correction. Student’s t-test for independent 
samples was used for assessing possible differences 
between mean values in the study groups. 
Prevalence ratios (PRs) with 95% confidence 
intervals (95% CIs) were estimated. Categorical 
data were described as absolute and percentage 
frequencies, then compared between groups using 
Pearson’s chi-square test or Fisher’s exact test, 
as appropriate. P-values < 0.05 were considered 
significant, and all tests were two-tailed.
RESULTS
Of all participants (n = 72), 61.1% were male. Mean 
age was 59 ± 15.5 years, ranging from 20 to 84 years. 
Most participants were older than 60 years (54.2%). 
The sample consisted mainly of self-reported white 
people (73.6%) with less than 8 years of education 
(94.4%) and employed in the metallurgical industry 
(20.8%) (Table 1).
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Table 1: Sociodemographic characteristics of patients 
treated at a Renal Replacement Therapy Unit in southern 
Brazil between 2014 and 2015.
Variable n = 72 %
Sex
Male 44 61.1
Female 28 38.9
Age (years)
≥ 61 39 54.2
20-60 33 45.8
Self-reported skin color
White 53 73.6
Non-white 19 26.4
Educational level
≤ 8 years of education 68 94.4
> 8 years of education 4 5.6
Occupation
Metalworker 15 20.8
Unemployed 7 9.7
Production assistant 7 9.7
Self-employed 5 6.9
Other 38 52.8
Hemodialysis service staff included four 
registered nurses with mean length of experience of 
10.2 ± 1.25 years and 26 licensed practical nurses 
with mean length of experience of 2.1 ± 2.19 years, 
which was a significant difference (p < 0.01). Of the 
9 hematomas identified in the sample, 1 (11.1%) 
was cannulated by a registered nurse and 8 (89.9%) 
were cannulated by licensed practical nurses 
(PR = 1.03; 95% CI: 0.77-1.38; p = 0.82).
A comparison between sociodemographic variables 
and comorbidities which could be associated with 
hematoma formation due to AVF is demonstrated 
in Table 2. No variable was associated with 
hematoma formation (i.e., all estimated PRs had 
p-values > 0.05), except for AVF time shorter than 
60 days (PR = 2.04; 95% CI: 1.28-3.27; p = 0.03), 
which was more common in the hematoma group 
(Table 2).
Table 2: Comparison of sociodemographic variables and risk factors in patients with or without hematomas (yes/no) 
treated at a Renal Replacement Therapy Unit in southern Brazil between 2014 and 2015.
Variable Yes (n = 31) No (n = 41) PR (95% CI) p-value*n % n %
Sex
Male 17 54.8 27 65.9 0.77 (0.46-1.31) 0.34
Female 14 45.2 14 34.1 1.00 ref.
Age (years)
≥ 61 16 51.6 23 56.1 0.90 (0.53-1.53) 0.71
20-60 15 48.4 18 43.9 1.00 ref.
Self-reported skin color
White 25 80.6 28 68.3 1.49 (0.73-3.07) 0.24
Non-white 6 19.4 13 31.7 1.00 ref.
Educational level
< 8 years of education 30 96.8 38 92.7 6.6 (0.98-44.79) 0.63
> 8 years of education 1 3.2 3 7.3 1.00 ref.
Hypertension
Yes 19 61.3 25 61.0 1.01 (0.58-1.73) 0.98
No 12 38.7 16 39.0 1.00 ref.
Diabetes
Yes 7 22.6 14 34.1 0.71 (0.36-1.38) 0.29
No 24 77.4 27 65.9 1.00 ref.
Nephrotic syndrome
Yes 5 16.1 4 9.8 1.34 (0.70-2.60) 0.42
No 26 83.9 37 90.2 1.00 ref.
CHF
Yes 4 12.9 2 4.9 1.63 (0.86-3.07) 0.22
No 27 87.1 39 95.1 1.00 ref.
Hepatitis C
Yes 1 3.2 1 2.4 1.16 (0.28-4.78) 0.84
No 30 96.8 40 97.6 1.00 ref.
AVF time
≤ 60 days 7 22.6 2 4.9 2.04 (1.28-3.27) 0.03
> 60 days 24 77.4 39 95.1 1.00 ref.
AVF: arteriovenous fistula; CHF: congestive heart failure; PR: prevalence ratio. Ref.: reference category. *Statistically significant result in bold.
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DISCUSSION
The present study evaluated variables possibly 
associated with hematomas in patients with 
AVF undergoing hemodialysis at a teaching hospital’s 
RRTU in Rio Grande do Sul. Sex, age, self-reported 
skin color, educational level, hypertension, diabetes, 
nephrotic syndrome, congestive heart failure, and 
hepatitis C were not statistically associated with 
hematoma formation. Nonetheless, presence of 
hematomas was associated with AVF time, suggesting 
caution in AVF management in patients undergoing 
hemodialysis.
According to the literature, variables such as 
age, educational level, diabetes, peripheral vascular 
disease, hypertension, coagulopathy, obesity, and 
smoking affect AVF maturation time and hematoma 
formation7,8,11-14. Consistent with our results, Lee et al. 
(2006)11 prospectively studied AVF infiltration in 
the United States and found no association of sex, 
race, and diabetes with occurrence of hematomas. 
However, in the same study, age was associated 
with hematomas11. No statistical association between 
educational level and presence of hematomas 
was found in the present study. Conversely, low 
educational level has already been associated 
with hematomas in patients with AVF in a study 
conducted in southern Brazil12. Furthermore, other 
studies have described low educational level as a 
risk factor for AVF complications7,13,14. The finding 
that most patients undergoing hemodialysis and 
showing complications have low educational level 
suggests that those with higher educational levels 
tend to seek health services earlier and practice 
self-care15,16. Additionally, age is an important 
factor for predisposition of hematomas in patients 
with AVF11, as the older the patient, the higher the 
likelihood of achieving this outcome, as a result 
of the aging process affecting the tunica intima of 
blood vessels16. This situation suggests that, with 
aging, vessels become fragile and, therefore, more 
susceptible to hematomas. However, this association 
was not found in the present study.
The cannulation method used in the present study 
for AVF access was the rope ladder technique, which 
rotates puncture sites in order to prevent formation 
of aneurysms, hematomas, and stenoses due to 
repeated damage to the vessel wall17,18. Cannulation 
care includes vascular access techniques, needle 
size, level of difficulty, and knowledge of what may 
cause hematomas, which can be developed through 
continuing education at health services14,18,19. Of the 
patients presenting with AVF hematomas, 6 (19.3%) 
had their AVF discontinued, requiring the use of a 
Shiley catheter for hemodialysis. Seven (22.6%) 
patients had AVF maturation time shorter than 
60 days. In several high-income countries, mean 
time for utilization of a fistula exceeds 60 days 
(98 days in the United States, 80 days in Spain, 
and 86 days in France). The few countries which 
have reported early AVF use are Japan (25 days) 
and Italy (27 days)20. Data show that insufficient AVF 
maturation contributes to hematoma formation20. 
Ideal maturation time would be longer than 60 days, 
but certain medical situations require early AVF use21. 
As hematomas frequently occur in the early stages 
of use of a fistula, the first cannulation should be 
performed by an experienced nurse22. Experienced 
nurses are capable of successfully predicting AVF 
maturation in 80% of the cases17-21. Thus, technical 
expertise and length of experience of the nurse in 
charge of creating an AVF is another relevant variable 
for reducing complications in hemodialysis access 
procedures13,17-19. In the present study, despite the 
lack of statistically significant difference probably 
because of the small sample size, the difference 
between number of hematomas in cannulations 
performed by registered nurses (11.1%) and number 
of hematomas in cannulations performed by licensed 
practical nurses (89.1%) was relevant. This finding 
reinforces that training and length of professional 
experience are essential for preventing hematomas.
The limitations of this study include its retrospective 
nature and sample size with low statistical power 
(n = 72). However, the present results may be useful 
for managing AVF time, with the aim of reducing 
hematoma formation and thus contributing to 
improving the quality of life of patients undergoing 
hemodialysis. Furthermore, future studies such 
as prospective cohorts with larger samples, more 
data on patients’ hemostatic state, and a wider 
scope of collected variables should provide greater 
understanding of AVF complications in patients 
undergoing hemodialysis.
CONCLUSION
AVF maturation time shorter than 60 days increases 
substantially the prevalence of hematomas at the 
cannulation site. Centers providing hemodialysis 
treatment must be aware of this finding.
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